Safety and efficacy of celiprolol in patients with COL3A1-positive vascular Ehlers-Danlos Syndrome (vEDS): A single center, retrospective, randomised controlled trial
Latest Information Update: 01 Apr 2021
At a glance
- Drugs Celiprolol (Primary)
- Indications Ehlers-Danlos syndrome
- Focus Adverse reactions; Therapeutic Use
- Acronyms BBEST trial
- Sponsors Acer Therapeutics
- 01 Feb 2021 Status has been changed to discontinued as per results published in the European Journal of Vascular and Endovascular Surgery.
- 01 Feb 2021 Results published in the European Journal of Vascular and Endovascular Surgery
- 24 Dec 2020 New trial record